BioLineRx Announces Q3 EPS of 0c, Unchanged from Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Should l Buy BLRX?
Q3 Revenue Decline: BioLineRx reported a Q3 revenue of $427k, a significant drop from $4.121M in the same period last year.
Joint Venture Announcement: The company established a joint venture with Hemispherian to expand its cancer treatment pipeline, focusing on glioblastoma alongside its ongoing PDAC program.
GLIX1 Development: Hemispherian's lead asset, GLIX1, targets DNA repair mechanisms in cancer cells and has shown strong efficacy in pre-clinical models.
Upcoming Clinical Trials: BioLineRx plans to initiate a Phase 1/2a first-in-human study for GLIX1 in Q1 of next year while continuing pre-clinical activities for potential trials in other cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLRX
Wall Street analysts forecast BLRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.750
Low
12.00
Averages
12.00
High
12.00
Current: 2.750
Low
12.00
Averages
12.00
High
12.00
No data
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioLineRx Partners with Hemispherian for Glioblastoma Trial
- New Drug Trial Partnership: BioLineRx has partnered with clinical-stage oncology firm Hemispherian to conduct a trial testing GLIX1 in patients with glioblastoma, with early data showing strong anti-tumor activity and good brain penetration, potentially offering a new treatment option for aggressive tumors.
- Clinical Trial Progress: BioLineRx is conducting a Phase 2b trial for Motixafortide, combining it with immunotherapy and standard chemotherapy, with an interim analysis expected later this year, indicating the drug's potential in pancreatic cancer treatment.
- Stock Price Surge: Shares of BioLineRx surged 10% in pre-market trading on Tuesday, marking the first test of the 50-day moving average since early March, reflecting positive market sentiment towards the company's new therapy.
- Future Outlook: Initial trial results for GLIX1 are expected in the first half of 2027, with BioLineRx's CEO stating that the drug may provide novel therapeutic approaches across multiple cancer indications, highlighting the company's strategic positioning in cancer treatment.
See More
BioLineRx Initiates First-in-Human Trial of GLIX1 for GBM
- Trial Initiation: BioLineRx has announced the initiation of a Phase 1/2a clinical trial for GLIX1, aiming to recruit up to 30 patients with recurrent and progressive glioblastoma, with initial data expected in H1 2027, thereby addressing a critical need for innovative treatment options in this area.
- Innovative Drug Mechanism: GLIX1, as a first-in-class oral small molecule, specifically targets DNA damage repair by restoring TET2 activity, demonstrating significant potential for application across various cancers, particularly in the treatment of glioblastoma.
- Strong Research Team: The clinical trial is led by a team of world-renowned glioblastoma researchers, including Dr. Alexandra Miller from NYU Langone Health and Dr. Roger Stupp from Northwestern University, ensuring a high level of rigor and expertise in the study.
- Urgent Market Need: Given the high unmet medical need for glioblastoma treatments, the development of GLIX1 not only aims to fill this gap but also presents significant market opportunities for BioLineRx, potentially advancing the company's position in the oncology sector.
See More
BIOLINERX LAUNCHES PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA (GBM) TREATMENT
- Announcement of Study: BiolinerX has initiated a Phase 1/2 study to evaluate the efficacy of GLIX1 in treating glioblastoma (GBM).
- Focus on Glioblastoma: The study aims to address the treatment challenges associated with glioblastoma, a highly aggressive brain tumor.
See More
BioLineRx Initiates GLIX1 Clinical Trial for Glioblastoma
- Clinical Trial Launch: BioLineRx is set to initiate its Phase 1/2a clinical trial of GLIX1 for glioblastoma by the end of this month, aiming to address unmet needs in cancer treatment, thereby enhancing the company's strategic positioning in oncology.
- Innovative Drug Mechanism: GLIX1 targets DNA damage response mechanisms, demonstrating significant efficacy in numerous pre-clinical models and a favorable safety profile in toxicology studies, which lays a solid foundation for its clinical application success.
- Market Opportunity: Patient enrollment in the ongoing CheMo4METPANC Phase 2b clinical trial for metastatic pancreatic cancer has accelerated, with BioLineRx anticipating an interim analysis in 2026, further validating its therapeutic potential in high-need tumor types and creating sustained value for the company.
- Financial Update: BioLineRx's 2025 fiscal year report indicates ongoing losses; however, the company is enhancing financial flexibility through capital financing and equity issuance, providing necessary funding for the development of GLIX1 and other candidates, ensuring continued growth in the competitive biopharmaceutical market.
See More
BioLineRx to Initiate GLIX1 Clinical Trial for Glioblastoma
- Clinical Trial Progress: BioLineRx is on track to initiate a Phase 1/2a clinical trial of GLIX1 for glioblastoma by the end of this month, targeting DNA damage response mechanisms, which could address unmet needs in cancer treatment and enhance the company's competitive edge in oncology.
- Enhanced Patent Protection: The company has received a Notice of Allowance from the USPTO for a key patent covering GLIX1 in 90% of cancer types, ensuring its development beyond glioblastoma and strengthening its market position, with patent protection expected to last until 2040.
- Strong Financial Position: As of December 31, 2025, BioLineRx reported $20.9 million in cash and cash equivalents, sufficient to fund operations into the first half of 2027, indicating robust financial health that supports ongoing R&D initiatives.
- Accelerated Collaborative Research: Enrollment in the CheMo4METPANC Phase 2b clinical trial for metastatic pancreatic cancer has accelerated, with an interim analysis expected in 2026, reflecting the company's proactive approach in developing new treatment options for patients in need.
See More
BioLineRx Reports FY EPS Beat Despite Revenue Plunge
- Earnings Beat: BioLineRx's FY report reveals a GAAP EPS of $0.00, exceeding expectations by $0.68, although this figure does not reflect the overall financial health of the company.
- Revenue Decline: The company reported revenue of $1.18 million, a staggering 95.9% year-over-year decrease, missing expectations by $0.3 million, indicating significant operational challenges.
- Cash Position: With $20.9 million on its balance sheet as of December 31, 2025, BioLineRx is projected to maintain its cash runway into the first half of 2027, suggesting short-term survival capability.
- Market Reaction: Despite the EPS beat, the sharp revenue decline may negatively impact investor confidence, highlighting the company's vulnerability in a competitive market.
See More
BioLineRx Partners with Hemispherian for Glioblastoma Trial
- New Drug Trial Partnership: BioLineRx has partnered with clinical-stage oncology firm Hemispherian to conduct a trial testing GLIX1 in patients with glioblastoma, with early data showing strong anti-tumor activity and good brain penetration, potentially offering a new treatment option for aggressive tumors.
- Clinical Trial Progress: BioLineRx is conducting a Phase 2b trial for Motixafortide, combining it with immunotherapy and standard chemotherapy, with an interim analysis expected later this year, indicating the drug's potential in pancreatic cancer treatment.
- Stock Price Surge: Shares of BioLineRx surged 10% in pre-market trading on Tuesday, marking the first test of the 50-day moving average since early March, reflecting positive market sentiment towards the company's new therapy.
- Future Outlook: Initial trial results for GLIX1 are expected in the first half of 2027, with BioLineRx's CEO stating that the drug may provide novel therapeutic approaches across multiple cancer indications, highlighting the company's strategic positioning in cancer treatment.
See More
BioLineRx Initiates First-in-Human Trial of GLIX1 for GBM
- Trial Initiation: BioLineRx has announced the initiation of a Phase 1/2a clinical trial for GLIX1, aiming to recruit up to 30 patients with recurrent and progressive glioblastoma, with initial data expected in H1 2027, thereby addressing a critical need for innovative treatment options in this area.
- Innovative Drug Mechanism: GLIX1, as a first-in-class oral small molecule, specifically targets DNA damage repair by restoring TET2 activity, demonstrating significant potential for application across various cancers, particularly in the treatment of glioblastoma.
- Strong Research Team: The clinical trial is led by a team of world-renowned glioblastoma researchers, including Dr. Alexandra Miller from NYU Langone Health and Dr. Roger Stupp from Northwestern University, ensuring a high level of rigor and expertise in the study.
- Urgent Market Need: Given the high unmet medical need for glioblastoma treatments, the development of GLIX1 not only aims to fill this gap but also presents significant market opportunities for BioLineRx, potentially advancing the company's position in the oncology sector.
See More
BIOLINERX LAUNCHES PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA (GBM) TREATMENT
- Announcement of Study: BiolinerX has initiated a Phase 1/2 study to evaluate the efficacy of GLIX1 in treating glioblastoma (GBM).
- Focus on Glioblastoma: The study aims to address the treatment challenges associated with glioblastoma, a highly aggressive brain tumor.
See More
BioLineRx Initiates GLIX1 Clinical Trial for Glioblastoma
- Clinical Trial Launch: BioLineRx is set to initiate its Phase 1/2a clinical trial of GLIX1 for glioblastoma by the end of this month, aiming to address unmet needs in cancer treatment, thereby enhancing the company's strategic positioning in oncology.
- Innovative Drug Mechanism: GLIX1 targets DNA damage response mechanisms, demonstrating significant efficacy in numerous pre-clinical models and a favorable safety profile in toxicology studies, which lays a solid foundation for its clinical application success.
- Market Opportunity: Patient enrollment in the ongoing CheMo4METPANC Phase 2b clinical trial for metastatic pancreatic cancer has accelerated, with BioLineRx anticipating an interim analysis in 2026, further validating its therapeutic potential in high-need tumor types and creating sustained value for the company.
- Financial Update: BioLineRx's 2025 fiscal year report indicates ongoing losses; however, the company is enhancing financial flexibility through capital financing and equity issuance, providing necessary funding for the development of GLIX1 and other candidates, ensuring continued growth in the competitive biopharmaceutical market.
See More
BioLineRx to Initiate GLIX1 Clinical Trial for Glioblastoma
- Clinical Trial Progress: BioLineRx is on track to initiate a Phase 1/2a clinical trial of GLIX1 for glioblastoma by the end of this month, targeting DNA damage response mechanisms, which could address unmet needs in cancer treatment and enhance the company's competitive edge in oncology.
- Enhanced Patent Protection: The company has received a Notice of Allowance from the USPTO for a key patent covering GLIX1 in 90% of cancer types, ensuring its development beyond glioblastoma and strengthening its market position, with patent protection expected to last until 2040.
- Strong Financial Position: As of December 31, 2025, BioLineRx reported $20.9 million in cash and cash equivalents, sufficient to fund operations into the first half of 2027, indicating robust financial health that supports ongoing R&D initiatives.
- Accelerated Collaborative Research: Enrollment in the CheMo4METPANC Phase 2b clinical trial for metastatic pancreatic cancer has accelerated, with an interim analysis expected in 2026, reflecting the company's proactive approach in developing new treatment options for patients in need.
See More
BioLineRx Reports FY EPS Beat Despite Revenue Plunge
- Earnings Beat: BioLineRx's FY report reveals a GAAP EPS of $0.00, exceeding expectations by $0.68, although this figure does not reflect the overall financial health of the company.
- Revenue Decline: The company reported revenue of $1.18 million, a staggering 95.9% year-over-year decrease, missing expectations by $0.3 million, indicating significant operational challenges.
- Cash Position: With $20.9 million on its balance sheet as of December 31, 2025, BioLineRx is projected to maintain its cash runway into the first half of 2027, suggesting short-term survival capability.
- Market Reaction: Despite the EPS beat, the sharp revenue decline may negatively impact investor confidence, highlighting the company's vulnerability in a competitive market.
See More
